Gotham Asset Management LLC cut its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 50.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,268 shares of the biotechnology company’s stock after selling 19,313 shares during the period. Gotham Asset Management LLC owned approximately 0.10% of Enanta Pharmaceuticals worth $693,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. GAM Holding AG acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter worth $108,000. Mason Street Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 7.0% during the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 212 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in shares of Enanta Pharmaceuticals by 3.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 110 shares during the period. SG Americas Securities LLC grew its stake in shares of Enanta Pharmaceuticals by 5.8% during the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 237 shares during the period. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Enanta Pharmaceuticals by 62.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 1,702 shares during the period. 66.24% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Gotham Asset Management LLC” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/gotham-asset-management-llc-has-693000-holdings-in-enanta-pharmaceuticals-inc-enta.html.
Enanta Pharmaceuticals, Inc. (NASDAQ ENTA) traded up 3.20% on Friday, reaching $49.65. The company’s stock had a trading volume of 412,055 shares. The stock’s 50 day moving average price is $46.02 and its 200 day moving average price is $37.87. Enanta Pharmaceuticals, Inc. has a 12 month low of $22.17 and a 12 month high of $50.39. The company’s market cap is $947.82 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The firm had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. During the same period last year, the business posted ($0.06) EPS. The business’s revenue was down 46.3% compared to the same quarter last year. Equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post $1.14 earnings per share for the current year.
A number of equities research analysts recently commented on ENTA shares. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 3rd. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research note on Tuesday, July 11th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Robert W. Baird lifted their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, August 8th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $45.25.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.